Disclosure of Pharmaceutical Revenue by Domestic Pharmaceuticals, Exports and Overseas Licensing

「In connection with the launch of linzagolix in Europe, the importance of overseas sales, including export sales of active pharmaceutical ingredients and other products, increased. Accordingly, from the end of the previous fiscal year, the company changed the categories used to disclose disaggregated revenue. Domestic pharmaceutical sales previously included in "Pharmaceutical sales," income from domestic license-out partners previously included in "Technology fees," and "Other" were reclassified as "Domestic pharmaceuticals." Export sales of active pharmaceutical ingredients and other products to overseas license-out partners previously included in "Pharmaceutical sales," and income from overseas license-out partners previously included in "Technology fees," were reclassified as "Exports and overseas licensing."」